top of page
 |
|---|
About Us
ABOUT US
NomoCan Pharmaceuticals offers First-in-Class targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective monoclonal antibody (mAb) drugs for the treatment of various cancers in order to “Bring Hope” to patients affected by this devastating disease.
PIPELINE
NMC-001
NMC-001 monoclonal antibody targets a specific pancreatic cancer marker and is able to selectively identify and diagnose pancreatic cancer in human. With a high affinity for its target, NMC-001 demonstrates potent anti-tumor efficiency in rodent models of pancreatic cancer.
Our Services
53,670
New Cases of
Pancreatic Cancer
diagnosed in 2017
43,090
Estimated Deaths of
Pancreatic Cancer
in 2017
8.2%
5-Year Survival
TEAM
TEAM
Ehsan S. Yazdi, Ph.D., M.P.H.
Co-Founder & Chief Executive Officer
Kamyar Neshvadian, M.S., F.R.M.
Chief Financial Officer
Jahanara Ali, Ph.D.
Chief Business Development Officer
Jean Paul Thiery, Ph.D.
Chief Scientific Officer
Lei Zhang, M.D.
Chief Clinical & Regulatory Officer
Owen O'Connor, M.D., Ph.D.
Board of Directors , Member
CANCER INFO
CONTACT
CONTACT
bottom of page